

AIDS 2020 Track B abstract submission categories

Track B – Clinical research	
Course of HIV disease	
B1	Acute and early infection
B2	Impact of co-factors (e.g., viral clade, tropism, genetic factors) on disease progression
B3	Morbidity, mortality and life expectancy in clinical research
Diagnostic and monitoring tools	
B4	HIV testing and retesting (e.g., point-of-care diagnostics)
B5	Viral load and CD4 monitoring
B6	Adherence testing
B7	Resistance to ART
B8	Diagnostics of co-infections and co-morbidities
B9	Biomarkers for the prediction of morbidity and mortality
Co-infections (including opportunistic infections)	
B10	Tuberculosis: Prevention, diagnosis, treatment
B11	Opportunistic infections (excluding TB): Bacterial, non-TB mycobacterial, viral and parasitic infections
B12	Viral hepatitis C
B13	Other viral hepatitis (e.g., A, B, D, E)
B14	STIs (including HPV)
Co-morbidities and complications (including those related to ART)	
B15	Neurologic disorders
B16	Depression and other psychiatric manifestations
B17	Malignancies (AIDS and non-AIDS)
B18	Cardiovascular disease
B19	Bone disease
B20	Renal disease
B21	Metabolic, lipid and endocrine complications (including lipodystrophy)
B22	Weight gain
B23	Hepatic complications (e.g., NASH)
B24	Mental health and HIV
B25	Ageing with HIV (including polypharmacy and frailty)
B26	Immune reconstitution disorders/immune reconstitution inflammatory syndrome (IRIS)
B27	Other ART complications and adverse reactions
B28	Other non-communicable diseases
B29	Co-morbidities and ART complications in key populations
Antiretroviral therapies in adults	
B30	ART in acute, first- and second-line therapies

B31	ART in highly treatment-experienced persons
B32	Regimen simplification and switch studies
B33	Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring
B34	Drug interactions
B35	Antiretroviral drug resistance
B36	Long-acting agents and other drug delivery systems (e.g., injectables, implants, microneedle patches)
B37	Adherence
B38	Ethical issues in clinical trials and treatment strategies
Other strategies and therapies	
B39	Therapeutic vaccine trials
B40	Cure interventions
B41	Complementary and traditional medicines
B42	Nutrition
Clinical issues specific to gender	
B43	Sex-specific issues of ART efficacy, adverse reactions and complications
B44	Pregnancy (clinical management issues and pharmacokinetics)
B45	Contraception
B46	Menopause
Clinical issues specific to paediatric and adolescent HIV	
B47	Diagnosis of HIV disease in paediatric and adolescent populations
B48	Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug monitoring in paediatric and adolescent populations
B49	Drug formulations for infants and children
B50	Clinical trials in paediatric and adolescent populations
B51	ARV management strategies in paediatric and adolescent populations
B52	Cure strategies in paediatric and adolescent populations
B53	Adherence in paediatric and adolescent populations
B54	Opportunistic infections in paediatric and adolescent populations
B55	TB/HIV co-infection in paediatric and adolescent populations (including treatment and prevention)
B56	HIV complications and co-morbidities in paediatric and adolescent populations
B57	HIV-associated co-infections and malignancies in paediatric and adolescent populations
B58	Behavioural health outcomes in paediatric and adolescent populations
B59	Mental health and neurocognition in paediatric and adolescent populations
B60	HIV-exposed uninfected children
B61	Transition of adolescents into adult care
Clinical issues specific to key populations and vulnerable populations	
B62	Clinical issues in men who have sex with men
B63	Clinical issues in sex workers
B64	Clinical issues in transgender people
B65	Clinical issues in people who use drugs

B66	Clinical issues in other vulnerable populations, including unstable settings (migrants) and incarcerated settings
B67	Ethical considerations related to clinical research with key populations and other vulnerable populations
COVID-19	
B68	Use of HIV-related antiviral agents in COVID-19 prevention and treatment
B69	Clinical manifestations and features of COVID-19 and HIV co-infection